FDA Seizes Illegal Medicines Worth ₹80,000 From Bhiwandi Eye Hospital

Mumbai: The Maharashtra Food and Drug Administration (FDA) seized illegal stock of medicines worth Rs80,000 from Aarav Eye Hospital in Bhiwandi on February 9 after a tip-off. This is the second such raid this year.

Earlier this month, the FDA busted a counterfeit medicine racket in Nagpur and seized 21,600 tablets of ciprofloxacin procured through a government contract. Samples of this drug were taken in March last year  but its results that it lacked any therapeutic value came in December.

In the present case, the eye hospital, owned by Dr Ashwin Bafna, didn’t have the licence to stock medicines. The hospital was established in 2005 and opened its second branch in Mira Road in 2017. The Bhiwandi branch opened in 2021.

A senior FDA official said that the pharmacist, Mohammad Ansari, didn’t have the licence required under the provisions of Drugs and Cosmetics Act, 1940 and Rules thereunder. Ansari initially told officials that he has the Pharmacists Registration Certificate issued by the Maharashtra Pharmacy Council but could not produce it; he later admitted not having any qualification as a pharmacist, the FDA official said. He added that the medicines seized can be sold only on the advice of a physician.

The official said, “Samples were drawn from the available stock and sale bills issued on and before February 9 were taken into custody.”

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre